Immunotherapy in mesothelioma - systematic review and meta-analysis of immunotherapy impact on OS and its correlation with PFS and ORR.
메타분석
2/5 보강
TL;DR
The results emphasize the importance of immunotherapy in mesothelioma and further support PFS as a surrogate endpoint.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
549 patients to evaluate the impact of immunotherapy on OS across different lines of therapy, histologic subtypes, and ECOG performance status, and to assess the correlation between OS, progression-free survival (PFS), and objective response rate (ORR).
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Additionally, a strong correlation was shown only between OS and PFS ( = 0.86, = 0.01). Our results emphasize the importance of immunotherapy in mesothelioma and further support PFS as a surrogate endpoint.
OpenAlex 토픽 ·
Occupational and environmental lung diseases
Pleural and Pulmonary Diseases
Air Quality and Health Impacts
The results emphasize the importance of immunotherapy in mesothelioma and further support PFS as a surrogate endpoint.
APA
Marko Skelin, Kaja Matić, et al. (2026). Immunotherapy in mesothelioma - systematic review and meta-analysis of immunotherapy impact on OS and its correlation with PFS and ORR.. Journal of chemotherapy (Florence, Italy), 38(3), 290-301. https://doi.org/10.1080/1120009X.2025.2492935
MLA
Marko Skelin, et al.. "Immunotherapy in mesothelioma - systematic review and meta-analysis of immunotherapy impact on OS and its correlation with PFS and ORR.." Journal of chemotherapy (Florence, Italy), vol. 38, no. 3, 2026, pp. 290-301.
PMID
40264298 ↗
Abstract 한글 요약
Mesothelioma has a poor prognosis, with a 5-year overall survival (OS) rate less than 5%. Immunotherapy has been proven as a promising alternative to platinum-based therapies in first-line treatment. Our systematic literature search included 7 randomized clinical trials involving 2,549 patients to evaluate the impact of immunotherapy on OS across different lines of therapy, histologic subtypes, and ECOG performance status, and to assess the correlation between OS, progression-free survival (PFS), and objective response rate (ORR). Immunotherapy significantly improved OS (HR 0.78, = 0.0005) with a similar benefit observed in first-line and second/later-line treatment ( = 0.25) as well as in all ECOG statuses ( = 0.32). A significantly greater benefit was observed in non-epithelioid compared to epithelioid mesothelioma ( = 0.002). Additionally, a strong correlation was shown only between OS and PFS ( = 0.86, = 0.01). Our results emphasize the importance of immunotherapy in mesothelioma and further support PFS as a surrogate endpoint.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.